UAB Cancer Prevention and Control Training Program (T32)
UAB Cancer Prevention and Control Training Program (T32)
批准号:
10427303
负责人:
Ritu Aneja
金额:
$44.4万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-07-13 至 2024-06-30
中文摘要
点击翻译按钮获取中文摘要
英文摘要
In 1988, the University of Alabama at Birmingham (UAB) Cancer Prevention and Control Training Program
(CPCTP) was established under an R25 mechanism and has trained 154 pre- and post-doctoral fellows over
the past 28 years. Located in the Deep South, an area marked by poverty and health disparities, the CPCTP
provides a critical bridge for students from diverse and disadvantaged backgrounds who seek research careers
in cancer prevention and control. Currently, 55% of CPCTP trainees are underserved minorities, and 65% are
female. Consonant with NCI's mission to address the nation's behavioral, biomedical, and clinical research
needs for a diverse workforce (PAR-16-152), we seek to transition our CPCTP to a T32 mechanism, so that we
can continue to prepare a diverse pool of highly-trained scientists who have made a major career commitment
to cancer prevention and control research (3 pre- & 3 post-doctoral fellows in years 1-2, and 4- pre & 4- post
doctoral fellows in years 3-5, with a planned duration of 3-years for each appointment). Over 90% of graduates
from our current cycle are actively engaged in research careers showing success. Our proposed T32 adds
many novel components to the CPCTP, while retaining those that have been key to our success, e.g., our
team science multidisciplinary approach and strong team mentorship from 32 faculty who are members of the
Cancer Control and Population Sciences and Cancer Chemoprevention Programs of the UAB Comprehensive
Cancer Center (CCC) - one of the nation's first 7 NCI-designated CCCs. Our efforts are supported by a solid
financial commitment by the UABCCC and our proposed aims are to: 1) recruit, educate, train and evaluate
pre- and postdoctoral fellows from diverse academic disciplines to conduct interdisciplinary research in cancer
prevention and control; 2) recruit a diverse cadre of well-qualified trainees who include members of minority
groups, (i.e., African-Americans, Latinos/ Hispanics, and other disadvantaged groups), and capitalize on UAB's
networks and resources to promote research in health disparities within the framework of cancer prevention
and control; 3)provide a specialized core didactic and tailored research curricula and rich learning opportunities
in cancer prevention and control (e.g., seminars, grant preparation/mock reviews), that complement (not
duplicate) other UAB training programs; 4) foster the development of independent research careers in cancer
prevention and control through mentoring by senior faculty who have established track records in funded
research; 5) further the development of all trainees via additional coursework, additional degrees (i.e., MSPH),
and obtaining independent research fellowships or career awards (e.g., F31/32, K99, DP5); 6) educate our
trainees in the Responsible Conduct of Research and in areas of professional development that will enhance
their future successes in research careers at universities, private institutions, or within the federal government;
and 7) emphasize interdisciplinary research training (team science) to enable trainees to gain competence in at
least two research areas and enhance their future ability to collaborate with professionals in other areas.
期刊论文(16)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1002/cam4.6710
发表时间:
2023-12
期刊:
Cancer medicine
影响因子:
4
作者:
[]
通讯作者:
Health behaviors and well-being among those "living" with metastatic cancer in Alabama.
阿拉巴马州转移性癌症“生活者”的健康行为和幸福感。
DOI:
10.1007/s00520-021-06583-1
发表时间:
2022
期刊:
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
影响因子:
--
作者:
[Bail,JenniferR, Bail,SumanthV, Cagle,Jessica, Tiesi,Koriann, Caffey,Jayla, Bakitas,Marie, Demark-Wahnefried,Wendy]
通讯作者:
Demark-Wahnefried,Wendy
DOI:
10.1111/jth.15284
发表时间:
2021-05
期刊:
Journal of thrombosis and haemostasis : JTH
影响因子:
--
作者:
[Avila L, Cullinan N, White M, Gaballah M, Cahill AM, Warad D, Rodriguez V, Tarango C, Hoppmann A, Nelson S, Kuhn T, Biss T, Weiss A, Temple M, Amaral JG, Amiri N, Xavier AC, Renzi S, Brandão LR]
通讯作者:
Brandão LR
Strategies in Overcoming Homologous Recombination Proficiency and PARP Inhibitor Resistance.
克服同源重组水平和PARP抑制剂耐药性的策略。
DOI:
10.1158/1535-7163.mct-20-0992
发表时间:
2021-09
期刊:
Molecular cancer therapeutics
影响因子:
5.7
作者:
[]
通讯作者:
DOI:
10.1002/cam4.4095
发表时间:
2021-08
期刊:
Cancer medicine
影响因子:
4
作者:
[Behring M, Ye Y, Elkholy A, Bajpai P, Agarwal S, Kim HG, Ojesina AI, Wiener HW, Manne U, Shrestha S, Vazquez AI]
通讯作者:
Vazquez AI
共 11 条
MARC Supplement at Georgia State University: Workforce Diversity Through Enhanced Mentoring
-
批准号:10394018
-
项目类别:
-
资助金额:$6.67万
-
财政年份:2019
-
负责人:Ritu Aneja
-
依托单位:
HSET as a racial disparity biomarker for TNBC patients
-
批准号:9898334
-
项目类别:
-
资助金额:$76.35万
-
财政年份:2019
-
负责人:Ritu Aneja
-
依托单位:
MARC at Georgia State University: Workforce Diversity through Honors Undergraduates
-
批准号:10166878
-
项目类别:
-
资助金额:$35.06万
-
财政年份:2019
-
负责人:Ritu Aneja
-
依托单位:
HSET as a racial disparity biomarker for TNBC patients
-
批准号:10632100
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2019
-
负责人:Ritu Aneja
-
依托单位:
HSET as a racial disparity biomarker for TNBC patients
-
批准号:10619237
-
项目类别:
-
资助金额:$55.13万
-
财政年份:2019
-
负责人:Ritu Aneja
-
依托单位:
Evaluation of centrosome amplification as a risk-predictor for breast cancer aggr
-
批准号:8968791
-
项目类别:
-
资助金额:$4.77万
-
财政年份:2015
-
负责人:Ritu Aneja
-
依托单位:
A novel racial disparity marker for risk prediction in triple negative breast cancer patients
-
批准号:8997736
-
项目类别:
-
资助金额:$20.75万
-
财政年份:2015
-
负责人:Ritu Aneja
-
依托单位:
Enhancing prognostic power of tumor grade by revisiting Ki67-mitosis relationship
-
批准号:8895609
-
项目类别:
-
资助金额:$7.4万
-
财政年份:2015
-
负责人:Ritu Aneja
-
依托单位:
Evaluation of centrosome amplification as a risk-predictor for breast cancer aggr
-
批准号:9149174
-
项目类别:
-
资助金额:$30.71万
-
财政年份:2014
-
负责人:Ritu Aneja
-
依托单位:
Evaluation of centrosome amplification as a risk-predictor for breast cancer aggr
-
批准号:8930931
-
项目类别:
-
资助金额:$30.71万
-
财政年份:2014
-
负责人:Ritu Aneja
-
依托单位:
Evaluation of centrosome amplification as a risk-predictor for breast cancer aggr
-
批准号:9339617
-
项目类别:
-
资助金额:$30.32万
-
财政年份:2014
-
负责人:Ritu Aneja
-
依托单位:
Evaluation of centrosome amplification as a risk-predictor for breast cancer aggr
-
批准号:8774495
-
项目类别:
-
资助金额:$30.71万
-
财政年份:2014
-
负责人:Ritu Aneja
-
依托单位:
Evaluation of HSET as a Novel Theranostic Target for Breast Cancer Therapy
-
批准号:8518273
-
项目类别:
-
资助金额:$28.18万
-
财政年份:2012
-
负责人:Ritu Aneja
-
依托单位:
Evaluation of HSET as a Novel Theranostic Target for Breast Cancer Therapy
-
批准号:9320098
-
项目类别:
-
资助金额:$4.56万
-
财政年份:2012
-
负责人:Ritu Aneja
-
依托单位:
Evaluation of HSET as a Novel Theranostic Target for Breast Cancer Therapy
-
批准号:9086291
-
项目类别:
-
资助金额:$29.98万
-
财政年份:2012
-
负责人:Ritu Aneja
-
依托单位:
Evaluation of HSET as a Novel Theranostic Target for Breast Cancer Therapy
-
批准号:8676746
-
项目类别:
-
资助金额:$29.08万
-
财政年份:2012
-
负责人:Ritu Aneja
-
依托单位:
Evaluation of HSET as a Novel Theranostic Target for Breast Cancer Therapy
-
批准号:9064260
-
项目类别:
-
资助金额:$4.81万
-
财政年份:2012
-
负责人:Ritu Aneja
-
依托单位:
Evaluation of HSET as a Novel Theranostic Target for Breast Cancer Therapy
-
批准号:8345799
-
项目类别:
-
资助金额:$29.98万
-
财政年份:2012
-
负责人:Ritu Aneja
-
依托单位:
Evaluation of HSET as a Novel Theranostic Target for Breast Cancer Therapy
-
批准号:8839353
-
项目类别:
-
资助金额:$4.67万
-
财政年份:2012
-
负责人:Ritu Aneja
-
依托单位:
Evaluation of HSET as a Novel Theranostic Target for Breast Cancer Therapy
-
批准号:8656663
-
项目类别:
-
资助金额:$4.11万
-
财政年份:2012
-
负责人:Ritu Aneja
-
依托单位:
海外基金